Previous 10 | Next 10 |
Zymeworks press release ( NYSE: ZYME ): Q2 Non-GAAP EPS of -$0.92 beats by $0.02 . Revenue of $5.44M (+207.3% Y/Y) misses by $0.02M . For further details see: Zymeworks Non-GAAP EPS of -$0.92 beats by $0.02, revenue of $5.44M misses by $0.02M
Zanidatamab zovodotin (ZW49) accepted for oral presentation of Phase 1 clinical data at European Society for Medical Oncology (ESMO) Congress in September Announced Early Research and Development (eR&D) day presentation and webcast for October 20 th , 2022 with focus on TO...
Today, we take a look at Zymeworks which recently was the target of a takeover attempt. The company has a new leadership team and is advancing its lead candidate via two pivotal trials. An investment analysis follows in the paragraphs below. Those who can make people...
Oral presentation will take place on Monday, September 12 at 5:25 pm Central European Summer Time (CEST) Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that data from the company’...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Dr. Paul Moore...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4 th , 2022. Following the announcement, management ...
Zymeworks ( ZYME ) has announced its intention to become a Delaware corporation which positions company for growth while helping to reduce complexity and certain administrative costs. It will also enhance long-term value for shareholders, help reduce certai...
Enhances alignment with US shareholder base and other peer biotechnology companies Positions company for growth while helping to reduce complexity and certain administrative costs The Company’s name, brand, and ticker symbol to remain unchanged Zym...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Zymeworks (NYSE:ZYME), a clinical-stage biotech focused on cancer therapeutics announced the appointment of biotech veteran Paul Moore as its new Chief Scientific Officer effective next month. Dr. Moore is expected to join Zymeworks (ZYME) on July 18, the company said, adding that he will bri...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...